Walgreens Boots Alliance (WBA)
(Delayed Data from NSDQ)
$8.77 USD
+0.03 (0.34%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $8.75 -0.02 (-0.23%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$8.77 USD
+0.03 (0.34%)
Updated Sep 6, 2024 04:00 PM ET
After-Market: $8.75 -0.02 (-0.23%) 7:58 PM ET
5-Strong Sell of 5 5
D Value D Growth A Momentum D VGM
Zacks News
Walgreens (WBA) Becomes Latest Retailer to Suspend Zantac Sales
by Christopher Vargas
Walgreens (WBA) announced today that they would be suspending the sales of Sanofi's (SNY) heartburn medication Zantac.
Rite Aid (RAD) Beats Q2 Earnings Estimates, Updates View
by Zacks Equity Research
Rite Aid (RAD) posts mixed second-quarter fiscal 2020 results. Further, management revises its view for the fiscal year.
Pharmacies & Drug Stores Industry Boasts Bright Prospects
by Urmimala Biswas
The Retail - Pharmacies and Drug Stores industry witnesses heavy consolidation.
Apple Roundup: Products, Security Issues, Analyst Opinion & Trillion-Dollar Valuation
by Sejuti Banerjea
Apple's new products, Goldman's reservations about the stock, iPhone security issues and its trillion-dollar valuation are the highlights of this roundup.
Walgreens' Retail Pharmacy Stays Firm Amid Reimbursement Woes
by Zacks Equity Research
Walgreens' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also gaining traction from a solid retail prescription market.
The Zacks Analyst Blog Highlights: Caterpillar, General Motors, Citigroup, Northrop Grumman and Walgreens Boots
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Caterpillar, General Motors, Citigroup, Northrop Grumman and Walgreens Boots
Top Analyst Reports for Caterpillar, General Motors & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Caterpillar (CAT), General Motors (GM) and Citigroup (C).
Is Walgreens Boots Alliance (WBA) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Stock Market News For Sep 3, 2019
by Zacks Equity Research
Markets closed higher on Friday as positive developments on the trade war front boosted the investor sentiment.
What to Expect from Kroger (KR) Q2 Earnings After Target, Walmart Impress
by Benjamin Rains
Let's take a look at what investors should expect from Kroger's (KR) Q2 earnings after Target and Walmart impressed Wall Street...
Walgreens Boots Alliance (WBA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Walgreens Boots Alliance (WBA) closed at $50.04, marking a +1.46% move from the previous day.
Walgreens (WBA) Expands Partnership With Retail Giant Kroger
by Zacks Equity Research
The extended partnership deal with Kroger will help Walgreens (WBA) strengthen its market presence.
Walgreens Boots Alliance (WBA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Walgreens Boots Alliance (WBA) closed at $51.16 in the latest trading session, marking a +1.35% move from the prior day.
Why Is Walgreens (WBA) Up 1% Since Last Earnings Report?
by Zacks Equity Research
Walgreens (WBA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
3 REITs to Buy Amid Q2 Earnings Season
by Benjamin Rains
Time is always right to consider real estate investment trusts or REITs, as they provide solid income for investors.
Microsoft Partners Providence, Boosts Healthcare Presence
by Zacks Equity Research
Microsoft (MSFT) to innovate technologies and offer computing infrastructure and artificial intelligence for shifting Providence's healthcare records to the cloud.
The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot
by Zacks Equity Research
The Zacks Analyst Blog Highlights: NIKE, Walgreens Boots Alliance, UnitedHealth, Pfizer and Home Depot
The Zacks Analyst Blog Highlights: Chevron, Merck, Walgreens Boots, FedEx and Loews
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Chevron, Merck, Walgreens Boots, FedEx and Loews
Walgreens Gains on Strategic Deals, Margin Pressure Remains
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division is witnessing comparable prescription growth and also benefiting from a strong retail prescription market.
Company News for Jun 28, 2019
by Zacks Equity Research
Companies in the news are: WBA, KBH, LYFT and CAG
Dow 30 Stock Roundup: Nike Earnings Disappoint, Walgreens Boots Margins Drop
by Swarup Gupta
The index suffered a disappointing week, declining over three straight trading sessions
Top Research Reports for Chevron, Merck & Walgreens Boots
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Chevron (CVX), Merck (MRK) and Walgreens Boots (WBA).
Will Amazon (AMZN) be Rite-Aid's (RAD) Bandage?
by Mitchell Moore
Rite Aid Corporation (RAD) posted its Q1 2020 earnings results on Wednesday, June 26, after market close. This report was disappointing with an adjusted loss of -$0.14 per share, a steep dive from our zacks Consensus Estimate of +$0.02.
Rite Aid (RAD) Incurs Loss in Q1, Revenues Decline Y/Y
by Zacks Equity Research
Rite Aid (RAD) incurs loss in first-quarter fiscal 2020. However, it reaffirms outlook for the fiscal year.
Walgreens Boots (WBA) Q3 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy USA division gains traction from comparable prescription volume growth and a sturdy retail prescription market.